Evidence map›Paper›PMID 26131587›Full record

ArticleCell cycle (Georgetown, Tex.)2015

SUMOylation of the C-terminal domain of DNA topoisomerase IIα regulates the centromeric localization of Claspin.

Hyunju Ryu, Makoto M Yoshida, Vinidhra Sridharan, Akiko Kumagai, William G Dunphy, Mary Dasso, Yoshiaki Azuma

Open access · bronzeAbstract read
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. SUMO: A Swiss Army Knife for Eukaryotic Topoisomerases.Frontiers in molecular biosciences · 2022
    Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Molecular mechanisms of topoisomerase 2 DNA-protein crosslink resolution.Cellular and molecular life sciences : CMLS · 2020
    Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Site-Specific Cleavage by Topoisomerase 2: A Mark of the Core Centromere.International journal of molecular sciences · 2018
    Article
  16. Non-Catalytic Roles of the Topoisomerase IIα C-Terminal Domain.International journal of molecular sciences · 2017
    Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Hyunju Ryua Department of Molecular Biosciences ; University of Kansas ; Lawrence , KS USA.
Makoto M Yoshida
Vinidhra Sridharan
Akiko Kumagai
William G Dunphy
Mary Dasso
Yoshiaki Azuma
University of Kansas · USNational Institutes of Health · USPasadena City College · US

Funding

SUMO family Ubiquitin-like Modifiers In Higher EukaryotesZIAHD001902 · NICHD · EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT · PI DASSO, MARY C. · 2009 to 2021
$6.3M
Role of ATR in Cell Cycle CheckpointsR01GM070891 · NIGMS · CALIFORNIA INSTITUTE OF TECHNOLOGY · PI DUNPHY, WILLIAM G · 2004 to 2018
$5.7M
ENZYMOLOGY OF MITOSIS PROMOTING FACTOR (MPF)R01GM043974 · NIGMS · CALIFORNIA INSTITUTE OF TECHNOLOGY · PI DUNPHY, WILLIAM G · 1990 to 2022
$4.0M
Enzymology of Mitosis Promoting Factor (MPF)R37GM043974 · NIGMS · CALIFORNIA INSTITUTE OF TECHNOLOGY · PI DUNPHY, WILLIAM G · 2002 to 2011
$4.0M
Regulation and function of PIASy mediated mitotic SUMOylation in vertebratesR01GM080278 · NIGMS · UNIVERSITY OF KANSAS LAWRENCE · PI AZUMA, YOSHIAKI · 2007 to 2011
$1.6M
NICHD NIH HHS HD001902NIGMS NIH HHS GM043974NIGMS NIH HHS GM070891NIGMS NIH HHS GM80278NIGMS NIH HHS R01 GM043974NIGMS NIH HHS R01 GM070891
6 · The paper itself

Abstract

DNA topoisomerase II (TopoII) regulates DNA topology by its strand passaging reaction, which is required for genome maintenance by resolving tangled genomic DNA. In addition, TopoII contributes to the structural integrity of mitotic chromosomes and to the activation of cell cycle checkpoints in mitosis. Post-translational modification of TopoII is one of the key mechanisms by which its broad functions are regulated during mitosis. SUMOylation of TopoII is conserved in eukaryotes and plays a critical role in chromosome segregation. Using Xenopus laevis egg extract, we demonstrated previously that TopoIIα is modified by SUMO on mitotic chromosomes and that its activity is modulated via SUMOylation of its lysine at 660. However, both biochemical and genetic analyses indicated that TopoII has multiple SUMOylation sites in addition to Lys660, and the functions of the other SUMOylation sites were not clearly determined. In this study, we identified the SUMOylation sites on the C-terminal domain (CTD) of TopoIIα. CTD SUMOylation did not affect TopoIIα activity, indicating that its function is distinct from that of Lys660 SUMOylation. We found that CTD SUMOylation promotes protein binding and that Claspin, a well-established cell cycle checkpoint mediator, is one of the SUMOylation-dependent binding proteins. Claspin harbors 2 SUMO-interacting motifs (SIMs), and its robust association to mitotic chromosomes requires both the SIMs and TopoIIα-CTD SUMOylation. Claspin localizes to the mitotic centromeres depending on mitotic SUMOylation, suggesting that TopoIIα-CTD SUMOylation regulates the centromeric localization of Claspin. Our findings provide a novel mechanistic insight regarding how TopoIIα-CTD SUMOylation contributes to mitotic centromere activity.

Indexed as

Adaptor Proteins, Signal TransducingAmino Acid SequenceAnimalsAntigens, NeoplasmCentromereDNA-Binding ProteinsDNA Topoisomerases, Type IIFemaleMaleMolecular Sequence DataSumoylationXenopus laevisXenopus ProteinsAdaptor Proteins, Signal TransducingAntigens, NeoplasmCLSPN protein, XenopusDNA-Binding ProteinsDNA Topoisomerases, Type IIXenopus ProteinscentromereClaspinmitosisSUMOtopoisomerase IIα

Identifiers

PMID26131587
PMCPMC4614044
OpenAlexW1903849698

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.